12 Hepatitis C and cirrhosis

Biomedical Research Reports

Volumn 2, Issue C, 2000, Pages 241-263

  Fattovich, Giovanna ^a   Schalm, Solko W ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957093455     PISSN: 18745326     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1874-5326(00)80016-2     Document Type: Article

References (72)

1. Alter M.J. Epidemiology of hepatitis C. Hepatology 26 (1997) 62S-65S
2. Tanaka K., Hirohata T., Koga S., et al. Hepatitis C and hepatitis B in the etiology of hepatocellular carcinoma in the Japanese population. Cancer Res 51 (1991) 2842-2847
3. De Bac C., Stroffolini T., Gaeta G.B., Taliani G., and Giusti G. Pathogenic factors in cirrhosis with and without hepatocellular carcinoma: a multicenter Italian study. Hepatology 20 (1994) 1225-1230
4. Nishiguchi S., Kuroki T., Nakatani S., et al. Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346 (1995) 1051-1055
5. International Interferon-α Hepatocellular Carcinoma Study Group. Effect of Interferon-α on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 351 (1998) 1535-1539
6. Mazzella G., Accogli E., Sottili S., et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 24 (1996) 141-147
7. Jouet P., Roudot-Thoraval F., Dhumeaux D., and Mètreau J.M. Le Group Français pour L'Etude du Traitment des Hèpatitis Chroniques NANB/C. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 106 (1994) 686-690
8. Hopf U., Moller B., Kuther D., et al. Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol 10 (1990) 69-76
9. Di Bisceglie A.M., Goodman Z.D., Ishak K.G., Hoofnagle J.H., Melpolder J.J., and Alter H.J. Long-term clinical and histopathological follow-up of chronic posttrasfusion hepatitis. Hepatology 14 (1991) 969-974
10. Tremolada F., Casarin C., Alberti A., et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 16 (1992) 273-281
11. Mattsson L., Sonnerborg A., and Weiland O. Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. Liver 13 (1993) 274-278
12. Kiyosawa K., Sodeyama T., Tanaka E., et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 12 (1990) 671-675
13. Tong M.J., El-Farra N.S., Reikes A.R., and Co R.L. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 332 (1995) 1463-1466
14. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 26 (1997) 2S-10S Suppl 1
15. Hèpatite C. dèpistage et traitement. Gastroenterol Clin Biol 20 (1997) S202-S211
16. Kenny-Walsh E., and for the Irish Hepatology Research Group. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 340 (1999) 1228-1233
17. Poynard T., Bedossa P., Opolon P for the OBSVIRC, METAVIR, and CLINIVIR and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 349 (1997) 825-832
18. Pol S., Fontaine H., Carnot F., et al. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatiits C: a comparison between immunocompetent and immunocompromised patients. J Hepatol 29 (1998) 12-19
19. Fong T.L., Di Bisceglie A.M., Waggoner J.G., Banks S.M., and Hoofnagle J.H. The significance of antibody to hepatitis C virus in patients with chronic hepatitis B. Hepatology 14 (1991) 64-67
20. Fattovich G., Tagger A., Brollo L., et al. Hepatitis C virus infection in chronic hepatitis B virus carriers. J Infect Dis 163 (1991) 400-402
21. Weltman M.D., Brotodihardjo A., Crewe E.B., et al. Coinfection with hepatitis B and C or B, C and D viruses results in severe chronic liver disease and responds poorly to interferon-α treatment. J Viral Hepatitis 2 (1995) 39-45
22. Wiley T.E., McCarthy M., Breidi L., McCarthy M., and Layden T.J. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 28 (1998) 805-809
23. Fattovich G., Giustina G., Degos F., et al. Morbidity and mortality in compensated cirrhosis C: a retrospective follow-up study of 384 patients. Gastroenterology 112 (1997) 463-472
24. Serfaty L., Aumaître H., Chazouillères O., et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 27 (1998) 1435-1440
25. Gordon S.C., Bayati N., and Silverman A.L. Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology 28 (1998) 562-567
26. EUROHEP: European Concerted Action on HCV-related Cirrhosis (2000)
27. Stroffolini T., Andreone P., Andriulli A., et al. Characteristics of hepatocellular carcinoma in Italy. J Hepatol 29 (1998) 944-952
28. Tinè F., Caltagirone M., Cammà C., et al. Clinical indicants of compensated cirrhosis: a prospective study. In: Dianzani M.U., and Gentilini P. (Eds). Chronic Liver Damage (1990), Elsevier, Amsterdam 187-198
29. Hoofnagle J.H. Hepatitis C: The clinical spectrum of disease. Hepatology 26 Suppl 1 (1997) 15S-20S
30. Haber M.M., West A.B., Haber A.D., and Reuben A. Relationship of aminotransferases to liver histological status in chronic hepatitis C. Am J Gastroenterol 90 (1995) 1250-1257
31. McCormick S.E., Goodman Z.D., Maydonovitch C.L., and Sjögren M.H. Evaluation of liver histology, ALT elevation, and HCV-RNA titer in patients with chronic hepatitis C. Am J Gastroenterol 91 (1996) 1516-1522
32. Lunel F., Musset L., Cacoub P., et al. Cryoglobulinemia in chronic liver disease: Role of hepatitis C virus and liver damage. Gastroenterology 106 (1994) 1291-1300
33. Pawlotsky J.M., Roudot-Thoraval F., Simmonds P., et al. Ann Intern Med 122 (1995) 169-173
34. Kew M.C. Hepatitis C virus and hepatocellular carcinoma in developing and developed countries. Viral. Hepatitis Rev 4 (1998) 259-269
35. Okuda K., Fujimoto I., Hanai A., and Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 47 (1987) 4967-4972
36. Simonetti R.G., Cammà C., Fiorello F., Politi F., D'Amico G., and Pagliaro L. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 36 (1991) 962-972
37. Koretz R.L., Abbey H., Coleman E., and Gitnick G. Non-A, non-B post-transfusion hepatitis: looking back in the second decade. Ann Intern Med 119 (1993) 110-115
38. Chiba T., Matsuzaki Y., Abei M., et al. The role of previous hepatitis B virus infection and heavy smoking in hepatitis C virus-related hepatocellular carcinoma. Am J Gastroenterol 91 (1996) 1195-1203
39. Fattovich G., Giustina G., Degos F., et al. Effectiveness of interferon alpha on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J Hepatol 27 (1997) 201-205
40. Christensen E. Multivariate survival analysis using Cox's regression model. Hepatology 7 (1987) 1346-1358
41. Colombo M., De Franchis R., Del Ninno E., et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 325 (1991) 675-680
42. Romeo R., Rumi M.G., Del Ninno E., and Colombo M. Hepatitis C virus genotype 1b and risk of hepatocellular carcinoma. Hepatology 26 (1997) 1077
43. Bruno S., Silini E., Crosignani A., et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 25 (1997) 754-758
44. Fattovich G., Ribero M.L., Pantalena M., et al. Hepatitis C virus genotype and clinical outcome of compensated cirrhosis type C. Hepatology 28 (1998) 408A
45. Benvegnù L., Fattovich G., Noventa F., et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. Cancer 74 (1994) 2442-2448
46. Tsai J.F., Jeng J.E., Ho M.S., et al. Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. Br J Cancer 76 (1997) 968-974
47. Donato F., Tagger A., Chiesa R., et al. Hepatitis B and C virus infection, alcohol drinking and hepatocellular carcinoma: a case-control study in Italy. Hepatology 26 (1997) 579-584
48. Hu K.Q., and Tong M.J. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 29 (1999) 1311-1316
49. Niederau C., Lange S., Heintges T., et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 28 (1998) 1687-1695
50. Seeff L.B., Buskell-Bales Z., Wright E.C., et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 327 (1992) 1906-1911
51. Saracco G., Rosina F., Abate M.L., et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-α 2b. Hepatology 18 (1993) 1300-1305
52. Saito T., Shinzawa H., Kuboki M., et al. A randomized controlled trial of human lymphoblastoid interferon in patients with compensated type C cirrhosis. Am J Gastroenterol 89 (1994) 681-686
53. Brouwer J.T., Nevens F., Kleter B., et al. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients. J Hepatol 28 (1998) 951-959
54. Ishimura N., Fukuda R., and Fukumoto S. Relationship between the intrahepatic expression of interferon-alpha receptor mRNA and the histological progress of hepatitis C virus-associated chronic liver diseases. J Gastroenterol Hepatol 11 (1996) 712-717
55. Mizukoshi E., Kaneko S., Yanagi M., et al. Expression of interferon alpha/beta receptor in the liver of chronic hepatitis C patients. J Med Virol 56 (1998) 217-223
56. Fukuda R., Ishimura N., Kushiyama Y., et al. Effectiveness of interferon-alpha therapy in chronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver. J Hepatol 26 (1997) 455-461
57. Morita K., Tanaka K., Saito S., et al. Expression of interferon receptor genes (IFNAR1 and IFNAR2 mRNA) in the liver may predict outcome after interferon therapy in patients with chronic genotype 2a or 2b hepatitis C virus infection. J Clin Gastroenterol 26 (1998) 135-140
58. Cooksley W. Interferon treatment of chronic hepatitis C with cirrhosis. J Viral Hepatitis 4 (1997) 85-88
59. Farrell G., Cooksley W.G., Dudley F.J., and Watson K. Efficacy and tolerance of a 6-month treatment course of daily interferon-alpha 2a for chronic hepatitis C with cirrhosis. The Australian Hepatitis C Study Group. J Viral Hepatitis 4 (1997) 317-323
60. Schalm S.W., Fattovich G., and Brouwer J.T. Therapy of hepatitis C: patients with cirrhosis. Hepatology 26 Suppl 1 (1997) 128S-132S
61. Valla D.C., Chevallier M., Marcellin P., et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 29 (1999) 1870-1875
62. Reichard O., Norkrans G., Fryden A., Braconier J.-H., Sönnerborg A., and Weiland O. Randomized, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet 351 (1998) 83-87
63. Davis G.L., Esteban-Mur R., Rustgi V.K., et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 339 (1998) 1493-1499
64. McHutchison J.G., Gordon S.C., Schiff E.R., et al. Interferon Alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339 (1998) 1485-1492
65. Poynard T., Marcellin P., Lee S.S., et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352 (1998) 1426-1432
66. Schalm S.W., Weiland O., Hansen B.E., et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Gastroenterology 117 (1999) 408-413
67. Gane E.J., Portmann B.C., Naoumov N.V., et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 334 (1996) 815-820
68. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (1996) 693-699
69. Bruix J., Castells A., Bosch J., et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 111 (1996) 1018-1022
70. Livraghi T., Giorgio T., Marin G., et al. Hepatocellular carcinoma in cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 197 (1995) 101-108
71. Colombo M. Treatment of hepatocellular carcinoma. J Viral Hepatitis 4 Suppl 1 (1997) 125-130
72. Llovet J.M., and Bruix J. Prognostic assessment and medical treatment of advanced hepatocellular carcinoma. In: Arroyo V., Bosch J., Bruguera M., Rodès J., and Sànchez Tapias J. (Eds). Treatment of liver diseases (1999), Masson, SA, Barcelona, Spain 345-354